Smartleaf Asset Management LLC Acquires 58 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Smartleaf Asset Management LLC boosted its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 10.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 635 shares of the company’s stock after buying an additional 58 shares during the quarter. Smartleaf Asset Management LLC’s holdings in IDEXX Laboratories were worth $262,000 as of its most recent SEC filing.

Other large investors also recently modified their holdings of the company. Middleton & Co. Inc. MA boosted its holdings in shares of IDEXX Laboratories by 98.1% in the fourth quarter. Middleton & Co. Inc. MA now owns 12,305 shares of the company’s stock worth $5,087,000 after acquiring an additional 6,095 shares during the period. Metis Global Partners LLC lifted its holdings in IDEXX Laboratories by 6.5% during the 4th quarter. Metis Global Partners LLC now owns 5,874 shares of the company’s stock worth $2,429,000 after purchasing an additional 359 shares in the last quarter. SVB Wealth LLC bought a new position in IDEXX Laboratories in the 4th quarter worth about $999,000. Peloton Wealth Strategists bought a new position in IDEXX Laboratories in the 4th quarter worth about $232,000. Finally, Proficio Capital Partners LLC purchased a new position in IDEXX Laboratories during the 4th quarter valued at about $62,391,000. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, EVP George Fennell sold 9,986 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $462.53, for a total value of $4,618,824.58. Following the completion of the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now directly owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the stock. Barclays increased their price target on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the stock an “overweight” rating in a report on Tuesday, February 4th. Piper Sandler increased their target price on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the stock a “neutral” rating in a research note on Monday, February 10th. Morgan Stanley reduced their price target on shares of IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a research report on Wednesday, January 29th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Thursday, February 27th. Finally, Leerink Partners assumed coverage on IDEXX Laboratories in a research note on Monday, December 2nd. They set an “outperform” rating and a $500.00 price objective for the company. Three analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $533.75.

IDEXX Laboratories Stock Down 1.0 %

IDXX opened at $437.23 on Thursday. The business’s fifty day simple moving average is $436.83 and its 200 day simple moving average is $450.33. IDEXX Laboratories, Inc. has a 52 week low of $398.50 and a 52 week high of $574.94. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $35.56 billion, a PE ratio of 40.98, a P/E/G ratio of 3.41 and a beta of 1.37.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.